Lessons from Novo Nordisk on the stampede for obesity drugs
Dos and don’ts on how to handle a gold rush
Paul Ingram, who manages a ranch in rural Texas, is not the type you would normally associate with a weight-loss fad. But a year ago he finally got fed up with lugging his 320lb (145kg) frame around all day in the heat. His family has a history of heart disease. As a result of covid-19, he had become painfully aware of the risks of obesity. His efforts to lose weight through diet and exercise had gone nowhere. “I needed some help.”
This article appeared in the Business section of the print edition under the headline “De Novo”
Business March 4th 2023
- How the titans of tech investing are staying warm over the VC winter
- Investors are going nuts for ChatGPT-ish artificial intelligence
- Foreign investors are being snagged by India’s tax net
- Artificial intelligence is reaching behind newspaper paywalls
- The uses and abuses of hype
- Lessons from Novo Nordisk on the stampede for obesity drugs
More from Business
Meet the ambitious wolf cubs of Wall Street
A duo of whippersnappers is taking on Goldman Sachs
What next for US Steel?
The faded industrial icon has few good options without a Nippon deal
Foxconn and other gadget-makers are expanding their empires
The world’s contract manufacturers are moving into new products and places
The signals of workplace submissiveness
Deference is all around you, unfortunately
America’s internet giants are being outplayed in the global south
From e-commerce to online banking, regional competitors are innovating rapidly
Will Mark Zuckerberg’s Trump gamble pay off?
He risks making enemies elsewhere